WHO ICTRP trial
A study of panobinostat in combination with bortezomib and dexamethasone in…
EUCTR2009-015507-52-SE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-015507-52-SE |
|---|---|
| Public title | A study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma |
| Scientific title | A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma |
| Primary sponsor | Novartis Pharma Services AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Greece;Finland;Spain;Austria;Italy;United Kingdom;France;Czech Republic;Belgium;Poland;Denmark;Germany;Netherlands;Sweden |
| Conditions | Multiple Myeloma (MM), relapsed or relapsed-and-refractory MedDRA version: 14.1 Level: PT Classification code 10028228 Term: Multiple myeloma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)… |
| Interventions | Product Name: panobinostat Product Code: LBH589 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Panobinostat CAS Number: 404950-80-7 Current Sponsor code: LBH589 Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Oct 15, 2009 |
| Target size | 762 |
| Secondary IDs | CLBH589D2308 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: